Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
8.585 USD | -0.89% |
|
+0.53% | +15.23% |
05-08 | Talis Biomedical Corporation Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
04-02 | North American Morning Briefing : Stocks Seen -2- | DJ |
Business Summary
Number of employees: 99
Sales per Business
USD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
Grant
80.7
%
| 1 | 24.1 % | 2 | 80.7 % | +48.45% |
Antigen Tests Products
19.3
%
| 4 | 75.9 % | 0 | 19.3 % | -88.72% |
Sales per region
USD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
United States
100.0
%
| 5 | 100.0 % | 2 | 100.0 % | -55.65% |
Managers
Managers | Title | Age | Since |
---|---|---|---|
Robert Kelley
CEO | Chief Executive Officer | 52 | 20-08-31 |
Director of Finance/CFO | 51 | 21-12-31 | |
Kim Popovits
BRD | Director/Board Member | 65 | 20-07-30 |
Emily Faucette
IRC | Investor Relations Contact | - | 20-12-31 |
- | - | ||
Matthew Pepe
HRO | Human Resources Officer | - | 21-04-30 |
Jill Green
LAW | General Counsel | - | 19-12-31 |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Matthew Posard
BRD | Director/Board Member | 56 | 16-02-29 |
Randal Scott
BRD | Director/Board Member | 66 | 13-12-31 |
Kim Popovits
BRD | Director/Board Member | 65 | 20-07-30 |
Robert Kelley
CEO | Chief Executive Officer | 52 | 20-08-31 |
Heiner Dreismann
BRD | Director/Board Member | 69 | 23-05-18 |
Rustem Ismagilov
FOU | Founder | 50 | 13-06-25 |
Raymond Cheong
BRD | Director/Board Member | 42 | 20-05-31 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 1,822,153 | 1,670,797 ( 91.69 %) | 0 | 91.69 % |
Stock B | 0 | 29,863,674 | 0 | 0 |
Company contact information
![address Talis Biomedical Corporation(TLIS)](https://cdn.zonebourse.com/static/address/118850454.png)
Sector
Sales per Business
1st Jan change | Capi. | |
---|---|---|
+15.23% | 15.78M | |
+18.34% | 45.51B | |
-9.11% | 38.52B | |
+38.08% | 38.13B | |
+26.49% | 30.74B | |
-8.64% | 26.03B | |
+11.67% | 25.92B | |
+47.08% | 14.13B | |
+33.98% | 12.73B | |
-7.21% | 11.29B |
- Stock Market
- Equities
- TLIS Stock
- Company Talis Biomedical Corporation